Philadelphia Chromosome Positive Recruiting Phase 2 Trials for Inotuzumab ozogamicin (DB05889)

Also known as: Philadelphia chromosome positive

IndicationStatusPhase
DBCOND0046287 (Philadelphia Chromosome Positive)Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03441061Inotuzumab Ozogamicin in Treating Participants With B-cell Acute Lymphocytic Leukemia With Positive Minimal Residual DiseaseTreatment